Sign In
Buy HCM
$9.99
-0.290 (-2.82%)
At Close: Jun 22, 2026
HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms
05:30am, Thursday, 28'th Nov 2024
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract r
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
11:30pm, Thursday, 21'st Nov 2024
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched
Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
02:51pm, Wednesday, 20'th Nov 2024
SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
04:30am, Wednesday, 20'th Nov 2024
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chao
SAN DIEGO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated
HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress
11:00pm, Tuesday, 05'th Nov 2024
HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the so
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
04:30am, Thursday, 31'st Oct 2024
— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer — — US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer —
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
04:30pm, Thursday, 17'th Oct 2024
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling
— New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer —
HUTCHMED (China) Ltd (HCM) Shares Up 2.9% on Oct 2
12:04pm, Wednesday, 02'nd Oct 2024
Shares of HUTCHMED (China) Ltd (HCM, Financial) surged 2.90% in mid-day trading on Oct 2. The stock reached an intraday high of $21.10, before settling at $20.58, up from its previous close of $20.00.
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
08:00am, Friday, 27'th Sep 2024
Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon's novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
03:00am, Tuesday, 24'th Sep 2024
— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer —
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced top-line data of EDG-7500 from the Phase 1 trial in he
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live w
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
08:00pm, Sunday, 08'th Sep 2024
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from sev
